Skip to main content

Advertisement

Log in

RETRACTED ARTICLE: Targeting EGFR in bladder cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope

This article was retracted on 13 September 2012

Abstract

Expression and overexpression of the epidermal growth factor receptor (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and ovarian cancers. In addition to gene amplification, point mutations within the kinase domain also occur. Previous reports indicate that the patient’s response to gefitinib depends on either the presence of mutations within the kinase domain of EGFR or the expression of the most frequent alteration, the truncated EGFR variant III (EGFRvIII). Therefore, it is important to determine if these EGFR alterations are present in urothelial carcinoma. The kinase domain of EGFR (exons 18–21) from 11 bladder cancer cell lines as well as from 75 patient tumors was analyzed by automated sequencing. No mutations were detected in all samples tested. Furthermore, analysis of EGFRvIII by immunohistochemistry revealed that almost half of all the patient samples expressed this truncation in a urothelial carcinoma tissue microarray. However, there have been previous reports of inconsistencies in detecting EGFRvIII by immunohistochemistry owing to the specificity of the antibodies and the methodologies utilized. Therefore, these results were validated by reverse transcription PCR, real-time PCR and western blot analysis. In these assays, none of the samples tested positive for EGFRvIII. Taken together, these results indicate that mutations within the tyrosine kinase domain of EGFR and expression of EGFRvIII are rare events in bladder cancer and therefore do not contribute to the malignant phenotype of this tumor. These results have clinical implications in selecting tyrosine kinase inhibitors for the therapy of urothelial carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Carpenter G, Cohen S (1990) Epidermal growth factor. J Biol Chem 265(14):7709–7712

    PubMed  CAS  Google Scholar 

  2. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137

    Article  PubMed  CAS  Google Scholar 

  3. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8(12):1197–1206

    Article  PubMed  CAS  Google Scholar 

  4. Araujo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, Pinto D, Lopes C, Medeiros R, Scagliotti GV (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer—a review of the literature. Oncologist 12(2):201–210

    Article  PubMed  CAS  Google Scholar 

  5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139

    Article  PubMed  CAS  Google Scholar 

  6. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD (1990) Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50(24):8017–8022

    PubMed  CAS  Google Scholar 

  7. Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87(21):8602–8606

    Article  PubMed  CAS  Google Scholar 

  8. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD (1997) Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324(Pt 3):855–861

    PubMed  CAS  Google Scholar 

  9. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6(10):1251–1259

    PubMed  CAS  Google Scholar 

  10. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91(16):7727–7731

    Article  PubMed  CAS  Google Scholar 

  11. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, Bigner DD, Weiner LM (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53(14):3217–3220

    Google Scholar 

  12. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55(23):5536–5539

    PubMed  CAS  Google Scholar 

  13. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ et al (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55(14):3140–3148

    PubMed  CAS  Google Scholar 

  14. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272(5):2927–2935

    Article  PubMed  CAS  Google Scholar 

  15. Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR (1995) Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55(19):4375–4382

    PubMed  CAS  Google Scholar 

  16. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ (1998) Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273(1):200–206

    Article  PubMed  CAS  Google Scholar 

  17. Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ (1996) Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13(1):85–96

    PubMed  CAS  Google Scholar 

  18. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HS (1996) Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271(41):25639–25645

    Article  PubMed  CAS  Google Scholar 

  19. Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2004) Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10(9):3216–3224

    Article  PubMed  CAS  Google Scholar 

  20. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5(2):257–265

    PubMed  CAS  Google Scholar 

  21. Bellmunt J, Hussain M, Dinney CP (2003) Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46(Suppl):S85–S104

    Article  PubMed  Google Scholar 

  22. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ (2007) Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 67(4):1430–1435

    Article  PubMed  CAS  Google Scholar 

  23. Pedersen MW, Pedersen N, Ottesen LH, Poulsen HS (2005) Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer 93(8):915–923

    Article  PubMed  CAS  Google Scholar 

  24. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, Xie B, Fan D, Bucana CD, Fidler IJ et al (1995) Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 154(4):1532–1538

    Article  PubMed  CAS  Google Scholar 

  25. Schmidt MH, Dikic I, Bogler O (2005) Src phosphorylation of Alix/AIP1 modulates its interaction with binding partners and antagonizes its activities. J Biol Chem 280(5):3414–3425

    Article  PubMed  CAS  Google Scholar 

  26. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M (2006) Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 12(15):4671–4677

    Article  PubMed  CAS  Google Scholar 

  27. Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M, Fuller G, Dinney C, Grossman HB, Baggerly K, Zhang W, Czerniak B (2005) Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest 85(4):532–549

    Article  PubMed  CAS  Google Scholar 

  28. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L (2005) Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 65(22):10524–10535

    Article  PubMed  CAS  Google Scholar 

  29. Rae JM, Scheys JO, Clark KM, Chadwick RB, Kiefer MC, Lippman ME (2004) EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat 87(1):87–95

    Article  PubMed  CAS  Google Scholar 

  30. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643–655

    Article  PubMed  CAS  Google Scholar 

  31. Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P (1999) Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol 36(5):393–400

    Article  PubMed  CAS  Google Scholar 

  32. Mellon K, Wright C, Kelly P, Horne CH, Neal DE (1995) Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 153(3 Pt 2):919–925

    PubMed  CAS  Google Scholar 

  33. Sriplakich S, Jahnson S, Karlsson MG (1999) Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int 83(4):498–503

    Article  PubMed  CAS  Google Scholar 

  34. Highshaw RA, McConkey DJ, Dinney CP (2004) Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Curr Opin Urol 14(5):295–300

    Article  PubMed  Google Scholar 

  35. Montgomery RB (2002) Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function. Int J Cancer 101(2):111–117

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Menashe Bar-Eli.

Additional information

This article has been retracted as substantial portions of this article were found to have been published previously by other authors.

G. J. Villares and M. Zigler contributed equally to this paper.

An erratum to this article can be found at http://dx.doi.org/10.1007/s00345-012-0940-z

About this article

Cite this article

Villares, G.J., Zigler, M., Blehm, K. et al. RETRACTED ARTICLE: Targeting EGFR in bladder cancer. World J Urol 25, 573–579 (2007). https://doi.org/10.1007/s00345-007-0202-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-007-0202-7

Keywords

Navigation